A 35-year-old man from Mumbai is admitted to the ICU with a 7-day history of fever, widespread blistering, and skin erosions affecting approximately 45% of his body surface area. He has involvement of the oral mucosa, conjunctivae, and genital region with severe pain. He developed these symptoms 3 weeks after starting phenytoin for newly diagnosed epilepsy. On examination, he has flaccid blisters, positive Nikolsky sign, and erythematous patches with areas of full-thickness epidermal detachment. His temperature is 40.1°C, heart rate 128/min, blood pressure 92/58 mmHg, and respiratory rate 28/min. Laboratory findings: WBC 14,200/μL, albumin 2.8 g/dL, creatinine 2.4 mg/dL, and blood cultures are pending. What is the most likely diagnosis, and what is the primary reason for the poor prognosis in this case?

Explanation

## Diagnosis: Toxic Epidermal Necrolysis (TEN) **Key Point:** TEN is the most severe form of severe cutaneous adverse reactions (SCAR), characterized by **≥30% body surface area (BSA) involvement** with full-thickness epidermal necrosis and systemic toxicity. This patient meets diagnostic criteria: - **45% BSA involvement** (>30% = TEN, not SJS) - **Mucosal involvement** (oral, conjunctival, genital) - **Positive Nikolsky sign** (hallmark of epidermal-dermal separation) - **Flaccid blisters** (not tense, as in pemphigoid) - **Fever, hemodynamic instability, acute kidney injury** - **Temporal relationship to phenytoin** (aromatic antiepileptic drugs are major TEN culprits) ## Classification of SCAR by BSA Involvement | Diagnosis | BSA Involvement | Mortality (%) | Key Features | |---|---|---|---| | **SJS** | <10% | 1–5% | Mucosal involvement, target lesions, limited skin involvement | | **SJS/TEN overlap** | 10–30% | 15–25% | Intermediate features, significant systemic involvement | | **TEN** | >30% | 25–50% | Extensive epidermal necrosis, severe systemic toxicity, sepsis risk | **High-Yield:** **Phenytoin is a major cause of TEN** — it is an aromatic antiepileptic drug (along with carbamazepine and lamotrigine) with high risk of SCAR, especially in the first 8 weeks of therapy. This patient is at 3 weeks, which is the peak risk window. ## Why Prognosis is Poor in TEN ### 1. Massive Fluid & Electrolyte Loss ```mermaid flowchart TD A[45% BSA epidermal loss]:::outcome --> B[Loss of skin barrier]:::outcome B --> C[Massive transepidermal water loss]:::action C --> D[Hypovolemia & shock]:::urgent D --> E[Acute kidney injury]:::urgent E --> F[Oliguria, hyperkalemia, acidosis]:::urgent ``` - **Albumin 2.8 g/dL** = severe protein loss from denuded skin - **Creatinine 2.4 mg/dL** = acute kidney injury (likely prerenal + direct tubular injury) - **BP 92/58 mmHg** = hypovolemic shock - Fluid requirements can exceed **3–4 L/m² BSA burned per 24 hours** (similar to major thermal burns) ### 2. Sepsis Risk **Clinical Pearl:** Loss of skin integrity removes the primary defense against bacterial and fungal infection. TEN patients are at **extremely high risk** for: - **Bacterial sepsis** (Staphylococcus aureus, Pseudomonas aeruginosa, Streptococcus pyogenes) - **Fungal sepsis** (Candida, Aspergillus) - **Septic shock** (mortality >50% if sepsis develops) This patient's **WBC 14,200/μL** and **fever 40.1°C** suggest early infection; **blood cultures pending** will guide antimicrobial therapy. ### 3. Multi-Organ Dysfunction | System | Complication | Mechanism | |---|---|---| | **Renal** | Acute kidney injury | Hypovolemia, myoglobinuria (from massive cell death), direct tubular toxicity | | **Respiratory** | ARDS, respiratory failure | Mucosal involvement (laryngeal edema), aspiration, sepsis-induced lung injury | | **Hepatic** | Hepatitis, coagulopathy | Direct drug toxicity (phenytoin), sepsis | | **Cardiac** | Arrhythmias, cardiogenic shock | Electrolyte derangements (K^+^, Ca^2+^, Mg^2+^), sepsis, myocarditis | | **Ocular** | Cicatricial pemphigoid, blindness | Conjunctival involvement with scarring | ### 4. Immunological Collapse **Mnemonic — TEN Pathophysiology: "CELL DEATH"** - **C**ytotoxic T cells (CD8^+^) infiltrate epidermis - **E**pidermal keratinocyte apoptosis (via FasL, TNF-α, granzyme B) - **L**oss of barrier function - **L**ymphocyte activation (Th1/Th17 response) - **D**rug-hapten formation (phenytoin metabolites bind to proteins) - **E**xtensive systemic inflammation (IL-6, TNF-α, IL-17) - **A**cute phase response (fever, leukocytosis) - **T**issue necrosis (full-thickness epidermal death) - **H**emodynamic instability ## Prognostic Scoring: TEN-Specific Mortality Index (TEN-SOM) **High-Yield:** Mortality in TEN correlates with: | Risk Factor | Points | |---|---| | Age >40 years | 1 | | Malignancy | 1 | | Heart rate >120/min | 1 | | Serum urea >10 mmol/L (>28 mg/dL) | 1 | | Serum glucose >14 mmol/L (>252 mg/dL) | 1 | | Bicarbonate <20 mEq/L | 1 | **Score ≥3 = mortality >35%** This patient has: - Age 35 (0 points) - Heart rate 128/min (1 point) - Creatinine 2.4 (likely urea elevated) (1 point) - **Estimated score ≥2** = **mortality 15–25%** at minimum; with 45% BSA, likely >35% ## Management Principles in TEN ```mermaid flowchart TD A[TEN diagnosed]:::outcome --> B[Discontinue offending drug]:::action B --> C[Transfer to ICU/burn unit]:::action C --> D[Aggressive fluid resuscitation]:::action D --> E[Monitor urine output 0.5-1 mL/kg/hr]:::action E --> F[Electrolyte & acid-base correction]:::action F --> G[Infection prevention & surveillance]:::action G --> H[Broad-spectrum antibiotics if sepsis suspected]:::action H --> I[Ophthalmology & ENT review]:::action I --> J{Systemic corticosteroids?}:::decision J -->|NOT recommended in TEN| K[Supportive care alone]:::action J -->|Controversial; avoid if possible| L[Increased infection risk]:::urgent K --> M[Nutritional support, pain control]:::action ``` **Warning:** **Systemic corticosteroids are NOT recommended in TEN** (unlike SJS). They increase infection risk without proven mortality benefit in TEN. This is a critical distinction from SJS management. [cite:Robbins 10e Ch 25; UpToDate: Toxic Epidermal Necrolysis]